BeOne Medicines Ltd. (ONC)
350.84
-2.62
(-0.74%)
USD |
NASDAQ |
Sep 18, 16:00
350.83
-0.01
(0.00%)
After-Hours: 20:00
BeOne Medicines Cash from Investing (Quarterly) : -49.41M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -49.41M |
| March 31, 2026 | -45.65M |
| December 31, 2025 | -38.60M |
| September 30, 2025 | -49.28M |
| June 30, 2025 | -67.07M |
| March 31, 2025 | -121.94M |
| December 31, 2024 | -93.60M |
| September 30, 2024 | -133.88M |
| June 30, 2024 | -111.03M |
| March 31, 2024 | -209.83M |
| December 31, 2023 | -62.58M |
| September 30, 2023 | -186.28M |
| June 30, 2023 | 67.80M |
| March 31, 2023 | 241.06M |
| December 31, 2022 | 38.54M |
| September 30, 2022 | 169.48M |
| June 30, 2022 | 657.28M |
| March 31, 2022 | 210.68M |
| December 31, 2021 | 108.71M |
| September 30, 2021 | -10.74M |
| June 30, 2021 | 251.60M |
| March 31, 2021 | 291.95M |
| Date | Value |
|---|---|
| December 31, 2020 | -86.92M |
| September 30, 2020 | -1.565B |
| June 30, 2020 | -429.90M |
| March 31, 2020 | -1.115B |
| December 31, 2019 | -23.89M |
| September 30, 2019 | 213.63M |
| June 30, 2019 | 196.01M |
| March 31, 2019 | 172.42M |
| December 31, 2018 | 213.24M |
| September 30, 2018 | -490.64M |
| June 30, 2018 | 34.13M |
| March 31, 2018 | -394.35M |
| December 31, 2017 | -68.24M |
| September 30, 2017 | -401.33M |
| June 30, 2017 | 84.23M |
| March 31, 2017 | 43.54M |
| December 31, 2016 | -170.72M |
| September 30, 2016 | 44.08M |
| June 30, 2016 | -135.55M |
| March 31, 2016 | 40.34M |
| December 31, 2015 | 7.302M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| AC Immune SA | -- |
| CRISPR Therapeutics AG | -55.66M |
| Idorsia Ltd. | -3.521M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 463.60M |
| Cash from Financing (Quarterly) | -6.128M |
| Free Cash Flow | 1.333B |
| Free Cash Flow Per Share (Quarterly) | 3.766 |
| Free Cash Flow to Equity (Quarterly) | 439.88M |
| Free Cash Flow to Firm (Quarterly) | 466.30M |
| Free Cash Flow Yield | 3.29% |